Ovid Therapeutics Inc OVID:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
3.06UNCH (UNCH)
Volume
2,030
Close
3.06quote price arrow up+0.01 (+0.33%)
Volume
219,979
52 week range
2.57 - 4.14
Loading...
  • Open3.05
  • Day High3.12
  • Day Low2.91
  • Prev Close3.05
  • 52 Week High4.14
  • 52 Week High Date08/22/23
  • 52 Week Low2.57
  • 52 Week Low Date11/30/23

Key Stats

  • Market Cap216.681M
  • Shares Out70.81M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change-4.97

KEY STATS

  • Open3.05
  • Day High3.12
  • Day Low2.91
  • Prev Close3.05
  • 52 Week High4.14
  • 52 Week High Date08/22/23
  • 52 Week Low2.57
  • 52 Week Low Date11/30/23
  • Market Cap216.681M
  • Shares Out70.81M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change-4.97

RATIOS/PROFITABILITY

  • EPS (TTM)-0.74
  • P/E (TTM)-4.12
  • Fwd P/E (NTM)-3.47
  • EBITDA (TTM)-58.713M
  • ROE (TTM)-47.57%
  • Revenue (TTM)391,689.986
  • Gross Margin (TTM)-
  • Net Margin (TTM)-13,362.34%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/03/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ovid Therapeutics Inc

 

Profile

MORE
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2...
Jeremy Levin Ph.D.
Chairman of the Board, Chief Executive Officer
Jason Tardio
Chief Operating Officer
Jeffrey Rona
Chief Business and Financial Officer
Address
441 NINTH AVENUE, 14TH FLOOR
New York, NY
10001
United States

Top Peers

SYMBOLLASTCHG%CHG
INMB
INmune Bio Inc
11.60-0.24-2.03%
PRLD
Prelude Therapeutics Inc
3.73-0.04-1.06%
MACK
Merrimack Pharmaceuticals Inc
14.98+0.24+1.63%
GALT
Galectin Therapeutics Inc
3.50-0.01-0.28%
DSGN
Design Therapeutics Inc
3.62+0.10+2.84%